Average stock performance after each discretionary buy, measured at 1, 3 and 6 months. 6 buys in history.
Holdings derived from the most recent reported transactions. Not adjusted for stock splits or share-class conversions.
| Issuer | Shares | Source | Last tx | Detail |
|---|---|---|---|---|
| AVANIR PHARMACEUTICALS | 235,000 | reported | 28 Nov 2014 | tx 19+739,556−80,000 |
| MEDIVATION, INC. | 29,166 | reported | 20 Apr 2011 | tx 27+600,590−142,076 |
| Neurogene Inc. | 12,050 | reported | 20 Feb 2026 | tx 7+147,200 |
| 89bio, Inc. | 0 | reported | 30 Oct 2025 | tx 61+3,587,450−4,055,215 |
| Date | Type | Issuer | Qty | Price | Signals |
|---|---|---|---|---|---|
| 20 Feb 2026 | GRANT_AWARD | Neurogene Inc. | 12,050 | 0.00 USD | deriv |
| 30 Oct 2025 | TENDER | 89bio, Inc. | 934,273 | — | |
| 30 Oct 2025 | GRANT_AWARD | 89bio, Inc. | 125,000 | 0.00 USD | |
| 30 Oct 2025 | OTHER | 89bio, Inc. | 300,000 | 0.00 USD | deriv |
| 30 Oct 2025 | OTHER | 89bio, Inc. | 605,000 | 0.00 USD | deriv |
| 30 Oct 2025 | OTHER | 89bio, Inc. | 848,000 | 0.00 USD | deriv |
| 30 Oct 2025 | OTHER | 89bio, Inc. | 132,242 | 0.00 USD | deriv |
| 30 Oct 2025 | OTHER | 89bio, Inc. | 120,231 | 0.00 USD | deriv |
| 30 Oct 2025 | OTHER | 89bio, Inc. | 220,000 | 0.00 USD | deriv |
| 30 Oct 2025 | OTHER | 89bio, Inc. | 203,750 | 0.00 USD | deriv |
| 30 Oct 2025 | OTHER | 89bio, Inc. | 170,000 | 0.00 USD | deriv |
| 01 Aug 2025 | TAX_WITHHOLDING | 89bio, Inc. | 55,836 | 9.16 USD | |
| 12 Jun 2025 | GRANT_AWARD | Neurogene Inc. | 12,050 | 0.00 USD | deriv |
| 17 Feb 2025 | TAX_WITHHOLDING | 89bio, Inc. | 3,249 | 10.57 USD | |
| 09 Feb 2025 | TAX_WITHHOLDING | 89bio, Inc. | 8,946 | 11.41 USD | |
| 01 Feb 2025 | GRANT_AWARD | 89bio, Inc. | 212,000 | 0.00 USD | |
| 01 Feb 2025 | TAX_WITHHOLDING | 89bio, Inc. | 9,598 | 9.60 USD | |
| 01 Feb 2025 | GRANT_AWARD | 89bio, Inc. | 200,000 | 0.00 USD | |
| 01 Feb 2025 | GRANT_AWARD | 89bio, Inc. | 848,000 | 0.00 USD | deriv |
| 06 Dec 2024 | PURCHASE | 89bio, Inc. | 5,000 | 7.89 USD | |
| 22 Nov 2024 | PURCHASE | 89bio, Inc. | 10,000 | 8.35 USD | first after silence |
| 17 Aug 2024 | TAX_WITHHOLDING | 89bio, Inc. | 4,601 | 8.04 USD | |
| 14 Jun 2024 | GRANT_AWARD | Neurogene Inc. | 7,700 | 0.00 USD | deriv |
| 01 Apr 2024 | SALE | 89bio, Inc. | 52,718 | 10.91 USD | |
| 01 Apr 2024 | EXERCISE | 89bio, Inc. | 25,000 | 1.93 USD |
2 purchases reported after at least 12 months of silence — most recent on 22 Nov 2024.